Core Insights - Hims & Hers Health is experiencing a turbulent period following a disappointing Q2 2025 earnings report, leading to projections of extended losses for the stock [1] - The company's stock price fell 12% in pre-market trading, closing at $55, down from $63.35, but remains over 150% higher year-to-date [1] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue increase to $544.8 million, which was below the expected $552 million [3] - Adjusted EPS was $0.17, surpassing the forecasted $0.15 [3] Market Sentiment - Investors reacted negatively to the revenue miss and ongoing regulatory concerns regarding the company's compounded GLP-1 drug offerings [4] - Wall Street analysts project an average price of $42.33 for HIMS stock over the next 12 months, indicating a 33.18% decline from its current price [5] Analyst Ratings - The consensus rating for HIMS stock is 'Hold', with one 'Buy', seven 'Hold', and two 'Sell' ratings [5] - Bank of America analyst Allen Lutz maintains a 'Sell' rating with a $28 price target, suggesting a potential 55% downside due to weak core business growth and integration risks [8] - TD Cowen's Jonna Kim reiterated a 'Hold' rating, raising the price target to $48, citing short-term challenges and long-term investments as key headwinds [9]